The UK Competition and Markets Authority (CMA) has provisionally found that pharmaceutical companies Auden Mckenzie and Waymade engaged in anti-competitive behavior relating to hydrocortisone tablets.
In a press release issued on Thursday, February 28, the CMA announced it had made a provisional finding that the two companies may have entered into an unlawful agreement.
Under the agreement, Auden Mckenzie may have made monthly payments to Waymade in exchange for Waymade not entering the 20mg hydrocortisone market, the CMA alleged.
Full Content: Gov UK
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
